Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease

BACKGROUND AND OBJECTIVE: Thyroid eye disease (TED) is characterized by inflammation/expansion of orbital tissues, proptosis, and diplopia. Teprotumumab is the first US Food and Drug Administration-approved therapy for TED, administered as an initial intravenous infusion of 10 mg/kg followed by 20 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Yan, Xu, Fengyan, Gao, Yuying, Bhatt, Nivedita, Chamberlain, Jason, Sile, Saba, Hammel, Suzy, Holt, Robert J., Ramanathan, Srini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332554/
https://www.ncbi.nlm.nih.gov/pubmed/33768488
http://dx.doi.org/10.1007/s40262-021-01003-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332554/
https://www.ncbi.nlm.nih.gov/pubmed/33768488
http://dx.doi.org/10.1007/s40262-021-01003-3

Ejemplares similares